Supernus Pharmaceuticals

Yahoo Finance • 25 days ago

Biogen Receives European Commission Approval for ZURZUVAE® (zuranolone), the First and Only Treatment Approved for Women with Postpartum Depression in Europe

Postpartum depression is a leading cause of maternal mortality in Europe1-2, and is one of the most common medical conditions associated with pregnancy3-5; up to 20% of women experience postpartum depressive symptoms6-11The approval of thi... Full story

Yahoo Finance • last month

SUPERNUS PHARMACEUTICALS INC (NASDAQ:SUPN) Emerges as a Top Affordable Growth Stock

Investors looking for growth chances at fair prices often consider methods that find companies with good expansion possibilities without high costs. The Affordable Growth method centers on stocks showing strong growth paths, good profitabi... Full story

Yahoo Finance • 2 months ago

Supernus Pharmaceuticals to Participate in September Investor Conferences

ROCKVILLE, Md., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, a... Full story

Yahoo Finance • 2 months ago

Here’s Third Avenue Small-Cap Value Fund’s Update on Supernus Pharmaceuticals (SUPN)

Third Avenue Management, an investment management company based in New York City, released its “Third Avenue Small-Cap Value Fund” second-quarter 2025 investor letter. A copy of the letter can be downloaded here. During the quarter, the fu... Full story

Yahoo Finance • 2 months ago

Supernus Pharmaceuticals price target raised to $43 from $38 at Stifel

Investing.com - Stifel raised its price target on Supernus Pharmaceuticals (NASDAQ:SUPN) to $43.00 from $38.00 on Wednesday, while maintaining a Hold rating on the stock. According to InvestingPro data, the stock is currently trading near... Full story

Yahoo Finance • 2 months ago

Supernus raises 2025 revenue guidance to $670M-$700M following Sage acquisition and strong core product growth

Earnings Call Insights: Supernus Pharmaceuticals (SUPN) Q2 2025 MANAGEMENT VIEW * CEO Jack A. Khattar stated that "Supernus continues to execute well against its growth plan and had a strong and very active second quarter." He highligh... Full story

Yahoo Finance • 2 months ago

Earnings call transcript: Supernus Q2 2025 revenue beats forecast, EPS misses

Supernus Pharmaceuticals reported its Q2 2025 earnings, revealing a mixed financial performance. The company achieved a revenue of $165 million, surpassing the forecast of $154.3 million by 7.26%. However, its earnings per share (EPS) fell... Full story

Yahoo Finance • 2 months ago

Supernus Announces Second Quarter 2025 Financial Results

Net sales of Qelbree® increased 31% in the second quarter of 2025, compared to the same period in 2024. Net sales of Qelbree of $77.6 million and $142.3 million in the second quarter and first six months of 2025, respectively.Net sales of... Full story

Yahoo Finance • 2 months ago

Supernus Pharmaceuticals Completes Acquisition of Sage Therapeutics

ROCKVILLE, Md., July 31, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN) (“Supernus”) today announced that it has successfully completed its previously announced acquisition of Sage Therapeutics, Inc. (Nasdaq: SAGE... Full story

Yahoo Finance • 2 months ago

Biogen rises as Alzheimer’s therapy drives Q2 beat

[Close up image of wooden cubes with alphabet Q2 on office desk.] mohd izzuan Biogen (NASDAQ:BIIB [https://seekingalpha.com/symbol/BIIB]) traded ~8% higher in the premarket on Thursday after the company posted better-than-expected financi... Full story

Yahoo Finance • 2 months ago

3 Stocks Estimated To Be Trading At A Discount Of Up To 49.9%

Over the last 7 days, the United States market has remained flat, yet it has experienced a notable increase of 17% over the past year with earnings forecasted to grow by 15% annually. In this environment, identifying stocks that are tradin... Full story

Yahoo Finance • 2 months ago

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Shares Could Be 50% Below Their Intrinsic Value Estimate

Key Insights Using the 2 Stage Free Cash Flow to Equity, Supernus Pharmaceuticals fair value estimate is US$66.72 Current share price of US$33.45 suggests Supernus Pharmaceuticals is potentially 50% undervalued Analyst price target for SU... Full story

Yahoo Finance • 3 months ago

Supernus Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Sage Therapeutics, Inc. Tender Offer

ROCKVILLE, Md., July 28, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc., a Delaware corporation (NASDAQ: SUPN) ("Supernus", and the "Company"), today announced that the required waiting period under the Hart-Scott-Rodino Antitru... Full story

Yahoo Finance • 3 months ago

Supernus Pharmaceuticals to Announce Second Quarter 2025 Financial Results and Host Conference Call and Webcast on August 5, 2025

ROCKVILLE, Md., July 22, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, t... Full story

Yahoo Finance • 3 months ago

Scotiabank downgrades Sage Therapeutics stock rating to Sector Perform

Investing.com - Scotiabank (TSX:BNS) downgraded Sage Therapeutics (NASDAQ:SAGE) from Sector Outperform to Sector Perform on Tuesday, while lowering its price target to $9.20 from $12.00. The stock, currently trading at $9.17, has shown r... Full story

Yahoo Finance • 3 months ago

Sector Update: Health Care Stocks Rise in Late Afternoon Trading

Health care stocks advanced late Tuesday afternoon, with the NYSE Health Care Index and the Health C PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 4 months ago

Sage Therapeutics price target lowered to $8.50 by TD Cowen

TD Cowen lowered its price target on Sage Therapeutics (NASDAQ:SAGE) stock to $8.50 from $9.00 on Monday, while maintaining a Hold rating on the biopharmaceutical company. The stock, currently trading at $9.1, has shown remarkable momentum... Full story

Yahoo Finance • 4 months ago

Truist raises Sage Therapeutics price target on Supernus acquisition

Truist Securities raised its price target on Sage Therapeutics (NASDAQ:SAGE) to $9.00 from $8.00 on Tuesday, while maintaining a Hold rating on the stock. The company’s shares, currently trading at $9.07, have surged nearly 30% in the past... Full story

Yahoo Finance • 4 months ago

Supernus stock rating reiterated as Piper Sandler questions Sage deal

Supernus Pharmaceuticals (NASDAQ:SUPN), currently valued at $2.03 billion and maintaining impressive gross margins of 88.42%, is acquiring Sage Therapeutics in an all-cash transaction valued at up to $795 million, according to a research n... Full story

Yahoo Finance • 4 months ago

Morning Movers: Sage Therapeutics surges after deal to be acquired by Supernus

Stock market futures are up slightly. Enthusiasm has been tempered by geopolitical risks and uncertainty ahead of Wednesday’s Federal Reserve decision. The Fed is widely expected to hold rates steady, but investors are laser-focused on Cha... Full story